February 20, 2024 12:20 PM ESTUpdated 12:57 PM
Manufacturing

Re­silience al­lo­cates $225M to ex­pand man­u­fac­tur­ing ca­pac­i­ty in Cincin­nati

Ayisha Sharma

News Reporter

Na­tion­al Re­silience is work­ing to ex­pand its clin­i­cal and com­mer­cial drug man­u­fac­tur­ing ca­pa­bil­i­ties to pro­vide more than 200 mil­lion units to its clients by 2025 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times